Listed

Avalo Therapeutics, Inc.

AVTXNasdaqCIK 1534120HealthcareFiscal year ends Dec 31

Latest reported revenue, Q4 FY2025$59.0kRevenue, Q4 FY2025, three months to 2025-12-31$59.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001534120-26-000011. Derived: 12-month figure less the 9-month figure.Report this figureThree months to Dec 31, 2025, from the 10-K filed Mar 23, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenuenot reported (Revenue not reported)No year-earlier figure to compare
  • Gross marginnot reported (Gross profit and Revenue not reported)No year-earlier figure to compare
  • Operating marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Net marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Diluted EPS−$0.83Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.83 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001534120-26-000049.Report this figure+56.8% on a year earlier
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Revenue$59.0kOperating margin −33461.0%
Diluted EPS−$0.83, Q2 FY2026
Avalo Therapeutics, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$k249Revenue, Q3 FY2024, three months to 2024-09-30$249.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001534120-25-000018.Report this figure192Revenue, Q4 FY2024, three months to 2024-12-31$192.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001534120-26-000011. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)0.0Revenue, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001534120-25-000018.Report this figure59.0Revenue, Q4 FY2025, three months to 2025-12-31$59.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001534120-26-000011. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)
Operating margin%(5165.1%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$12.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001534120-25-000018.Revenue: $249.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001534120-25-000018.Report this figure(6932.8%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$13.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-23, accession 0001534120-26-000011. Derived: 12-month figure less the 9-month figure.Revenue: $192.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001534120-26-000011. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue of zero not reported)(33461.0%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$19.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-23, accession 0001534120-26-000011. Derived: 12-month figure less the 9-month figure.Revenue: $59.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001534120-26-000011. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)
Net margin%9251.8%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $23.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001534120-25-000018.Revenue: $249.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001534120-25-000018.Report this figure(18405.7%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$35.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-23, accession 0001534120-26-000011. Derived: 12-month figure less the 9-month figure.Revenue: $192.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001534120-26-000011. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue of zero not reported)(23254.2%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$13.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-23, accession 0001534120-26-000011. Derived: 12-month figure less the 9-month figure.Revenue: $59.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001534120-26-000011. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)
Diluted EPS$ per share(2.83)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$2.83 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001534120-25-000018.Report this figurenot reported (Diluted EPS not reported)(1.25)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$1.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001534120-26-000033.Report this figure(1.92)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$1.92 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001534120-26-000049.Report this figure(2.19)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$2.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001534120-25-000018.Report this figurenot reported (Diluted EPS not reported)(0.98)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.98 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001534120-26-000033.Report this figure(0.83)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.83 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001534120-26-000049.Report this figure
Free cash flow$knot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$59.0kOperating margin −123601.7%
Diluted EPS−$5.84, FY2025
Free cash flow−$26.8m, FY2022
Avalo Therapeutics, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m5.4Revenue, FY2021, twelve months to 2021-12-31$5.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-29, accession 0001628280-23-009630.Report this figure18.1Revenue, FY2022, twelve months to 2022-12-31$18.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-29, accession 0001628280-24-013786.Report this figure1.9Revenue, FY2023, twelve months to 2023-12-31$1.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-20, accession 0001628280-25-013986.Report this figure0.4Revenue, FY2024, twelve months to 2024-12-31$441.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001534120-26-000011.Report this figure0.1Revenue, FY2025, twelve months to 2025-12-31$59.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001534120-26-000011.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(1521.6%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$82.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-03-29, accession 0001628280-23-009630.Revenue: $5.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-29, accession 0001628280-23-009630.Report this figure(207.4%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$37.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-29, accession 0001628280-24-013786.Revenue: $18.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-29, accession 0001628280-24-013786.Report this figure(1421.6%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$27.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-20, accession 0001628280-25-013986.Revenue: $1.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-20, accession 0001628280-25-013986.Report this figure(15535.6%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$68.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-23, accession 0001534120-26-000011.Revenue: $441.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001534120-26-000011.Report this figure(123601.7%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$72.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-23, accession 0001534120-26-000011.Revenue: $59.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001534120-26-000011.Report this figure
Net margin%(1563.1%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$84.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-03-29, accession 0001628280-23-009630.Revenue: $5.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-29, accession 0001628280-23-009630.Report this figure(230.8%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$41.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-29, accession 0001628280-24-013786.Revenue: $18.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-29, accession 0001628280-24-013786.Report this figure(1639.5%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$31.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-20, accession 0001628280-25-013986.Revenue: $1.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-20, accession 0001628280-25-013986.Report this figure(7965.8%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$35.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-23, accession 0001534120-26-000011.Revenue: $441.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001534120-26-000011.Report this figure(132642.4%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$78.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-23, accession 0001534120-26-000011.Revenue: $59.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001534120-26-000011.Report this figure
Diluted EPS$ per sharenot reported (Diluted EPS not reported)(1063.00)Diluted EPS, FY2022, twelve months to 2022-12-31−$1063.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-29, accession 0001628280-24-013786.Report this figure(113.58)Diluted EPS, FY2023, twelve months to 2023-12-31−$113.58 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-20, accession 0001628280-25-013986.Report this figure(20.91)Diluted EPS, FY2024, twelve months to 2024-12-31−$20.91 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-23, accession 0001534120-26-000011.Report this figure(5.84)Diluted EPS, FY2025, twelve months to 2025-12-31−$5.84 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-23, accession 0001534120-26-000011.Report this figure
Free cash flow$m(71.0)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$70.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-03-29, accession 0001628280-23-009630.Capital expenditure: $113.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-29, accession 0001628280-23-009630.Report this figure(26.8)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$26.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-29, accession 0001628280-24-013786.Capital expenditure: $95.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-29, accession 0001628280-23-009630.Report this figurenot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Avalo Therapeutics, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
FMR LLC2026-06-30$94.3m5,100,216Added+2,220,735
BlackRock, Inc.2026-06-30$80.7m4,365,553Added+4,038,471
Deep Track Capital, LP2026-06-30$66.7m3,610,000New+3,610,000
Caligan Partners LP2026-06-30$58.5m3,163,866Added+1,528,843
TCG Crossover Management, LLC2026-06-30$55.8m3,017,120Added+2,278,737
Affinity Asset Advisors, LLC2026-06-30$53.6m2,900,000Added+1,559,160
STATE STREET CORP2026-06-30$53.4m2,889,287Added+2,817,633
FARALLON CAPITAL MANAGEMENT, L.L.C.2026-06-30$46.2m2,498,000Added+1,582,000
Point72 Asset Management, L.P.2026-06-30$44.1m2,387,026Added+1,470,884
Avoro Capital Advisors LLC2026-06-30$43.1m2,333,333Added+923,333

Recent filings

All 1,209 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Avalo Therapeutics, Inc., recent filings
FiledFormWhat it isAccession number
2026-08-0607:03 ET10-QQuarterly reportPeriod 2026-06-300001534120-26-000049
2026-08-0607:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001534120-26-000048
2026-06-2307:01 ET8-K5.02 Departure or appointment of officers or directors0001534120-26-000044
2026-06-1607:18 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001534120-26-000042
2026-06-1216:06 ET8-K3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits0001534120-26-000040
2026-06-0816:19 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001534120-26-000036
2026-05-1307:02 ET10-QQuarterly reportPeriod 2026-03-310001534120-26-000033
2026-05-1307:00 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001534120-26-000032
2026-05-0719:38 ET8-K1.01 Entry into a material agreement; 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-26-056482
2026-05-0516:01 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001534120-26-000028

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 23, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
1534120
Tickers
AVTX
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company
Former names
Cerecor Inc. (to 2021-08-18)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:18 ET. Listed shows no prices and gives no investment advice.